Intake of FDA-Approved Drug Modulates Disease Progression in Alzheimer’s Model - Neuroscience News
3/23/2022 12:00:00 AM3 years 1 month ago
by https://www.facebook.com/neurosciencenews
by https://www.facebook.com/neurosciencenews
Niaspan, an FDA-approved drug, limits disease progression in lab models of Alzheimer's disease.
Summary: Niaspan, an FDA-approved drug, limits disease progression in lab models of Alzheimer’s disease. Source: Indiana University Indiana University School of Medicine researchers have found that… [+3971 chars]
full article...